Revance Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Revance Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2014 to Q3 2024.
  • Revance Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $4.58M, a 48.6% decline year-over-year.
  • Revance Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $35.2M, a 20.1% decline year-over-year.
  • Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49.2M, a 6.02% decline from 2022.
  • Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $52.3M, a 20.5% increase from 2021.
  • Revance Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $43.4M, a 19.2% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $35.2M $4.58M -$4.33M -48.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $39.5M $6.03M -$7.45M -55.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $47M $8.76M -$2.19M -20% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $49.2M $15.8M +$5.11M +47.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $44.1M $8.91M -$9.08M -50.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $53.2M $13.5M +$4.22M +45.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $48.9M $11M -$3.41M -23.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $52.3M $10.7M -$194K -1.78% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $52.5M $18M +$7.45M +70.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $45.1M $9.26M -$2.11M -18.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $47.2M $14.4M +$3.76M +35.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $43.4M $10.9M -$958K -8.07% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $44.4M $10.5M -$139K -1.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $44.5M $11.4M +$4.02M +54.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $40.5M $10.6M +$4.06M +62.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $36.5M $11.9M +$6.84M +136% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $29.6M $10.7M +$6.37M +148% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $23.2M $7.35M +$2.93M +66.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $20.3M $6.54M +$2.39M +57.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $17.9M $5.04M +$1.19M +30.9% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $16.7M $4.3M +$211K +5.16% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $16.5M $4.42M +$248K +5.94% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $16.3M $4.16M +$1K +0.02% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $16.3M $3.85M +$441K +12.9% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $15.8M $4.09M +$946K +30.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 $14.9M $4.17M +$653K +18.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $14.2M $4.16M +$1M +31.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $13.2M $3.41M +$441K +14.9% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 $12.8M $3.15M +$391K +14.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-02
Q2 2017 $12.4M $3.52M +$267K +8.21% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 $12.1M $3.16M +$178K +5.98% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $12M $2.97M -$2.11M -41.5% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $14.1M $2.76M +$165K +6.37% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-03
Q2 2016 $13.9M $3.25M +$845K +35.1% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-04
Q1 2016 $13M $2.98M +$660K +28.5% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 $12.4M $5.07M +$3.14M +162% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-02
Q3 2015 $9.25M $2.59M +$305K +13.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 $8.95M $2.41M +$908K +60.6% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-05
Q1 2015 $8.04M $2.32M +$1.51M +186% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 $6.53M $1.94M Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 $2.29M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 $1.5M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 $810K Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.